Real-World Revascularization Strategy for Left Main Coronary Artery: Surgery or PCI?

There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD).

Estrategia de revascularización del tronco de la coronaria izquierda en el Mundo Real: ¿cirugía o angioplastia? 

In the European Society of Cardiology guidelines, PCI is classified as Ia (LMCAD with low-complexity coronary disease) or IIa indication (intermediate complexity), whereas, according to the American Heart Association it is classified as IIa evidence (when PCI revascularization has results equivalent to MRS). Despite evidence and recommendations, the treatment of LMCAD remains a controversial matter. Moreover, there is little information of real-world observational studies comparing these two interventions (PCI and MRS).

This retrospective study aims at comparing long-term results of PCI and MRS in patients with LMCAD.

The primary endpoint (PEP) was all-cause mortality. Secondary endpoints (SEP) were major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, readmission for acute myocardial infarction (AMI), stroke, and repeat revascularization. There was also a safety endpoint, which was mortality at 30 days, defined as in-hospital or 30-day death after a revascularization procedure.

Read also: Secondary Mitral Regurgitation: Stages of Heart Failure and Prognostic Implications after Transcatheter Edge-to-Edge Repair

Between 2008 and 2020, 2526 patients were included in the PCI arm and 21,287 in the MRS arm. Propensity score matching (PSM) was conducted to homogenize both arms. A total of 1128 patients were analyzed in each arm. Before conducting the PSM, the PCI arm had a more elderly population that included more women; however, this population had a lower coronary disease rate.

Regarding short-term results, there were no significant differences in early death (P = 0.0750), in-hospital death (P = 0.913), and stroke (P = 0.201). Nevertheless, the PCI arm had higher AMI rates (P = 0.007).

Regarding results at 7 years, survival was 46 % for the PCI arm and 64 % for the MRS arm (P < 0.0001). The cumulative incidence of AMI was greater in the PCI arm compared with the MRS arm (P < 0.0001), and the need for repeat revascularization was more frequent in the PCI arm (P < 0.0001). Stroke incidence was lower in the PCI arm compared with the MRS arm (P < 0.001).

Conclusion

MRS is associated with better long-term results compared with PCI in patients with LMCAD. These results indicate that MRS should be the preferred revascularization strategy for patients who meet surgery requirements.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Real-World Examination of Revascularization Strategies for Left Main Coronary Disease in Ontario, Canada.

Reference: Derrick Y. Tam, MD et al J Am Coll Cardiol Intv 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...